Genomtec S.A. Total Liabilities
Genomtec S.A. total liabilities. Based on the latest financial reports, Genomtec S.A. (GMT) has total liabilities worth zł6.01 Million PLN (≈ $1.65 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Genomtec S.A. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genomtec S.A. (2019–2024)
Total liabilities of Genomtec S.A. from 2019 to 2024. This chart illustrates how Genomtec S.A.'s total liabilities have evolved over time, based on quarterly financial data.
Genomtec S.A. Competitors by Total Liabilities
The table below lists competitors of Genomtec S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Niobay Metals Inc
V:NBY
|
Canada | CA$187.11K |
|
Ruffer Investment Company Limited
LSE:RICA
|
UK | GBX6.50 Million |
|
Prairie Provident Resources Inc
TO:PPR
|
Canada | CA$174.93 Million |
|
Nexen Corp
KO:005725
|
Korea | ₩3.20 Trillion |
|
Warisan TC Holdings Bhd
KLSE:5016
|
Malaysia | RM661.03 Million |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
USA | $2.62 Billion |
|
KINGFISH COMPANY EO -01
F:93G
|
Germany | €122.14 Million |
|
Kingsrose Mining Ltd
AU:KRM
|
Australia | AU$5.84 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Genomtec S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Genomtec S.A. (GMT) total assets.
Liquidity & Leverage Metrics
Genomtec S.A. Total Liabilities Ratios Explained
Genomtec S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomtec S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomtec S.A. (2019–2024)
The table below shows the annual total liabilities of Genomtec S.A. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł9.44 Million ≈ $2.60 Million |
+23.09% |
| 2023-12-31 | zł7.67 Million ≈ $2.11 Million |
+11.68% |
| 2022-12-31 | zł6.87 Million ≈ $1.89 Million |
+97.47% |
| 2021-12-31 | zł3.48 Million ≈ $957.20K |
+93.33% |
| 2020-12-31 | zł1.80 Million ≈ $495.11K |
-0.13% |
| 2019-12-31 | zł1.80 Million ≈ $495.77K |
-- |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more